GlassScriptPhysician profile
Jake Schlemmer
NPI 1851824684
$866.08
in general payments reported to CMS, 2019-2025
22 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.21 · 2022: $338 · 2023: $157 · 2024: $140 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $141.61 | 2021-2025 | |
| Novo Nordisk INC | $137.27 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $71.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.77 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $57.41 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.09 | 2022-2023 | Xifaxan |
| Abbvie INC. | $42.86 | 2023-2024 | Qulipta |
| Astellas Pharma US INC | $29.72 | 2023 | Veozah |
| Boston Scientific Corporation | $27.78 | 2022-2025 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $27.71 | 2022-2025 | Eliquis |
| Alexion Pharmaceuticals, INC. | $25.96 | 2024 | Strensiq |
| Antares Pharma, INC. | $23.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.47 | 2023 | Gvoke Hypopen |
| Amgen INC. | $19.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.57 | 2025 | Airsupra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.14 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.88 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.59 | 2024 | |
| Sumitomo Pharma America, INC. | $14.82 | 2023 | Gemtesa |
| Exact Sciences Corporation | $14.62 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Schlemmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.